Reports Q2 revenue $110.792M, consensus $106.65M. “Our continued commercial execution resulted in another quarter of solid growth for CAPLYTA. Due to CAPLYTA’s strong performance to date and our confidence in continued growth, we are raising our 2023 full year net product sales guidance,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We have also continued to progress our pipeline including our clinical and preclinical development programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ITCI:
- Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
- Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
- Intra-Cellular price target raised to $73 from $70 at Needham
- Intra-Cellular price target raised to $80 from $74 at UBS
- Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference